Search results
Results from the WOW.Com Content Network
Best case scenario, the average shelf-life of vitamins is two years, Davis-Cadogan adds. There are some vitamins that come with special storage instructions, so it’s important to thoroughly read ...
Epidemiologists have found evidence to suggest that long-term, high-dose supplementation with B6 and B12 may increase risk of developing lung cancer.
A review of clinical trials in the treatment of colds with small and large doses of Vitamin C has established that there is no evidence that it decreases the incidence of common colds. [28] After 33 years of research, it is still not established whether vitamin C can be used as a treatment for cancer. [29]
Vitamin deficiencies may result in disease conditions: goiter, scurvy, osteoporosis, impaired immune system, disorders of cell metabolism, certain forms of cancer, symptoms of premature aging, and poor psychological health (including eating disorders), among many others. [82] Excess levels of some vitamins are also dangerous to health.
Since its discovery, vitamin C has been considered almost a panacea by some, [14] although this led to suspicions of it being overhyped by others. [15] Vitamin C has long been promoted in alternative medicine as a treatment for the common cold, cancer, polio, and various other illnesses. The evidence for these claims is mixed.
Researchers found that taking calcium and vitamin D supplements lowered a woman’s long-term risk of dying from cancer by 7%, but increased the risk of death due to heart disease by 6%. The study ...
In the United States, overdose exposure to all formulations of "vitamins" (which includes multi-vitamin/mineral products) was reported by 62,562 individuals in 2004 with nearly 80% of these exposures in children under the age of 6, leading to 53 "major" life-threatening outcomes and 3 deaths (2 from vitamins D and E; 1 from a multivitamin with ...
No statistically significant effects were found for any specific cancers or cancer mortality. The 95% CI of the hazard ratio implied a benefit of between 14% and .2% over placebo. In absolute terms the difference was 1.3 cancer diagnoses, per 1000 years of life (18.3-17 events, respectively). The median follow up time was 11.2 years. [3]